JP2005523901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523901A5 JP2005523901A5 JP2003565479A JP2003565479A JP2005523901A5 JP 2005523901 A5 JP2005523901 A5 JP 2005523901A5 JP 2003565479 A JP2003565479 A JP 2003565479A JP 2003565479 A JP2003565479 A JP 2003565479A JP 2005523901 A5 JP2005523901 A5 JP 2005523901A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrrolidin
- quinolin
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- -1 hydroxy, amino, acetylamino Chemical group 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 229940086609 Lipase inhibitor Drugs 0.000 claims 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 4
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000001246 bromo group Chemical group Br* 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002346 iodo group Chemical group I* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 125000005884 carbocyclylalkyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 2
- 229960001243 orlistat Drugs 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical group C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims 1
- QWLSZMHCDHNODH-UHFFFAOYSA-N 2,2-dimethyl-n-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)propanamide Chemical compound C=12C=CC(NC(=O)C(C)(C)C)=CC2=NC(C)=CC=1N1CCCC1 QWLSZMHCDHNODH-UHFFFAOYSA-N 0.000 claims 1
- BLIFSQROOJKZEL-UHFFFAOYSA-N 2-methyl-4-pyrrolidin-1-yl-n-(thiophen-2-ylmethyl)quinolin-7-amine Chemical compound C=12C=CC(NCC=3SC=CC=3)=CC2=NC(C)=CC=1N1CCCC1 BLIFSQROOJKZEL-UHFFFAOYSA-N 0.000 claims 1
- HUDWZKOJYXHMGZ-UHFFFAOYSA-N 2-methyl-n-(2-methylpropyl)-4-pyrrolidin-1-ylquinolin-7-amine Chemical compound C=1C(C)=NC2=CC(NCC(C)C)=CC=C2C=1N1CCCC1 HUDWZKOJYXHMGZ-UHFFFAOYSA-N 0.000 claims 1
- PGBJQQCVESMMIM-UHFFFAOYSA-N 3-methyl-n-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)butanamide Chemical compound C=1C(C)=NC2=CC(NC(=O)CC(C)C)=CC=C2C=1N1CCCC1 PGBJQQCVESMMIM-UHFFFAOYSA-N 0.000 claims 1
- YIAYAZXGXKSBRM-UHFFFAOYSA-N 4-[(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)amino]benzonitrile Chemical compound C=12C=CC(NC=3C=CC(=CC=3)C#N)=CC2=NC(C)=CC=1N1CCCC1 YIAYAZXGXKSBRM-UHFFFAOYSA-N 0.000 claims 1
- MVJVQMRGBDNHOW-SFHVURJKSA-N 4-[(3s)-3-ethoxypyrrolidin-1-yl]-2-methyl-n-pyridin-3-ylquinolin-7-amine Chemical compound C1[C@@H](OCC)CCN1C1=CC(C)=NC2=CC(NC=3C=NC=CC=3)=CC=C12 MVJVQMRGBDNHOW-SFHVURJKSA-N 0.000 claims 1
- HAYLQPXSZLDLQK-KRWDZBQOSA-N 4-[(3s)-3-methoxypyrrolidin-1-yl]-2-methyl-n-pyridin-3-ylquinolin-7-amine Chemical compound C1[C@@H](OC)CCN1C1=CC(C)=NC2=CC(NC=3C=NC=CC=3)=CC=C12 HAYLQPXSZLDLQK-KRWDZBQOSA-N 0.000 claims 1
- SRNUHYAZNVNSKZ-HXUWFJFHSA-N 4-[[4-[(2r)-2-(methoxymethyl)pyrrolidin-1-yl]-2-methylquinolin-7-yl]amino]benzonitrile Chemical compound COC[C@H]1CCCN1C1=CC(C)=NC2=CC(NC=3C=CC(=CC=3)C#N)=CC=C12 SRNUHYAZNVNSKZ-HXUWFJFHSA-N 0.000 claims 1
- YAVPLAQEQDEVLN-IBGZPJMESA-N 4-[[4-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-2-methylquinolin-7-yl]amino]benzonitrile Chemical compound C=12C=CC(NC=3C=CC(=CC=3)C#N)=CC2=NC(C)=CC=1N1CCC[C@H]1CO YAVPLAQEQDEVLN-IBGZPJMESA-N 0.000 claims 1
- VDQKHTJHDWFTLL-FQEVSTJZSA-N 4-[[4-[(3s)-3-ethoxypyrrolidin-1-yl]-2-methylquinolin-7-yl]amino]benzonitrile Chemical compound C1[C@@H](OCC)CCN1C1=CC(C)=NC2=CC(NC=3C=CC(=CC=3)C#N)=CC=C12 VDQKHTJHDWFTLL-FQEVSTJZSA-N 0.000 claims 1
- CLTYJMAMVSIRCT-UHFFFAOYSA-N 4-cyano-n-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)benzamide Chemical compound C=12C=CC(NC(=O)C=3C=CC(=CC=3)C#N)=CC2=NC(C)=CC=1N1CCCC1 CLTYJMAMVSIRCT-UHFFFAOYSA-N 0.000 claims 1
- DRZKMEMZVIYCJK-UHFFFAOYSA-N 4-fluoro-n-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)benzamide Chemical compound C=12C=CC(NC(=O)C=3C=CC(F)=CC=3)=CC2=NC(C)=CC=1N1CCCC1 DRZKMEMZVIYCJK-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000006307 alkoxy benzyl group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- QFTGJUGWYARDAE-UHFFFAOYSA-N n-(2,2-dimethylpropyl)-2-methyl-4-pyrrolidin-1-ylquinolin-7-amine Chemical compound C=12C=CC(NCC(C)(C)C)=CC2=NC(C)=CC=1N1CCCC1 QFTGJUGWYARDAE-UHFFFAOYSA-N 0.000 claims 1
- LTWIZCJNLPPYKO-UHFFFAOYSA-N n-(2,6-dimethyl-4-pyrrolidin-1-ylquinolin-7-yl)furan-2-carboxamide Chemical compound C=12C=C(C)C(NC(=O)C=3OC=CC=3)=CC2=NC(C)=CC=1N1CCCC1 LTWIZCJNLPPYKO-UHFFFAOYSA-N 0.000 claims 1
- BLPGQNHKFXUPKN-UHFFFAOYSA-N n-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)cyclopropanecarboxamide Chemical compound C=12C=CC(NC(=O)C3CC3)=CC2=NC(C)=CC=1N1CCCC1 BLPGQNHKFXUPKN-UHFFFAOYSA-N 0.000 claims 1
- HUACSPMJAPGPNA-UHFFFAOYSA-N n-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)methanesulfonamide Chemical compound C=12C=CC(NS(C)(=O)=O)=CC2=NC(C)=CC=1N1CCCC1 HUACSPMJAPGPNA-UHFFFAOYSA-N 0.000 claims 1
- UPTVWHNDQOIPGI-UHFFFAOYSA-N n-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)pyridine-3-carboxamide Chemical compound C=12C=CC(NC(=O)C=3C=NC=CC=3)=CC2=NC(C)=CC=1N1CCCC1 UPTVWHNDQOIPGI-UHFFFAOYSA-N 0.000 claims 1
- SCJXKKGZNILJAE-UHFFFAOYSA-N n-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)pyridine-3-sulfonamide Chemical compound C=12C=CC(NS(=O)(=O)C=3C=NC=CC=3)=CC2=NC(C)=CC=1N1CCCC1 SCJXKKGZNILJAE-UHFFFAOYSA-N 0.000 claims 1
- PMJPHEAEMAOVPH-UHFFFAOYSA-N n-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)pyridine-4-carboxamide Chemical compound C=12C=CC(NC(=O)C=3C=CN=CC=3)=CC2=NC(C)=CC=1N1CCCC1 PMJPHEAEMAOVPH-UHFFFAOYSA-N 0.000 claims 1
- OEXALPOPMDOTQQ-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-2-methyl-4-pyrrolidin-1-ylquinolin-7-amine Chemical compound COC1=CC=CC=C1CNC1=CC=C(C(=CC(C)=N2)N3CCCC3)C2=C1 OEXALPOPMDOTQQ-UHFFFAOYSA-N 0.000 claims 1
- MOCIVXBVXMYZJB-HNNXBMFYSA-N n-[4-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-2-methylquinolin-7-yl]furan-2-carboxamide Chemical compound C=12C=CC(NC(=O)C=3OC=CC=3)=CC2=NC(C)=CC=1N1CCC[C@H]1CO MOCIVXBVXMYZJB-HNNXBMFYSA-N 0.000 claims 1
- CGXHQPCFJBXZHQ-KRWDZBQOSA-N n-[4-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-2-methylquinolin-7-yl]pyridine-3-carboxamide Chemical compound C=12C=CC(NC(=O)C=3C=NC=CC=3)=CC2=NC(C)=CC=1N1CCC[C@H]1CO CGXHQPCFJBXZHQ-KRWDZBQOSA-N 0.000 claims 1
- NSMBHSBPIXQKEZ-INIZCTEOSA-N n-[4-[(2s)-2-(methoxymethyl)pyrrolidin-1-yl]-2-methylquinolin-7-yl]cyclopropanecarboxamide Chemical compound COC[C@@H]1CCCN1C1=CC(C)=NC2=CC(NC(=O)C3CC3)=CC=C12 NSMBHSBPIXQKEZ-INIZCTEOSA-N 0.000 claims 1
- RVXIRRIRHVHATB-INIZCTEOSA-N n-[4-[(3s)-3-ethoxypyrrolidin-1-yl]-2-methylquinolin-7-yl]cyclopropanecarboxamide Chemical compound C1[C@@H](OCC)CCN1C1=CC(C)=NC2=CC(NC(=O)C3CC3)=CC=C12 RVXIRRIRHVHATB-INIZCTEOSA-N 0.000 claims 1
- QYBCQTIWTCSCPL-HNNXBMFYSA-N n-[4-[(3s)-3-ethoxypyrrolidin-1-yl]-2-methylquinolin-7-yl]propanamide Chemical compound C1[C@@H](OCC)CCN1C1=CC(C)=NC2=CC(NC(=O)CC)=CC=C12 QYBCQTIWTCSCPL-HNNXBMFYSA-N 0.000 claims 1
- RGEWMROOVIYXOZ-UHFFFAOYSA-N n-methyl-n-(2-methyl-4-pyrrolidin-1-ylquinolin-7-yl)pyridine-3-carboxamide Chemical compound C=1C=C2C(N3CCCC3)=CC(C)=NC2=CC=1N(C)C(=O)C1=CC=CN=C1 RGEWMROOVIYXOZ-UHFFFAOYSA-N 0.000 claims 1
- 125000001326 naphthylalkyl group Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02001967 | 2002-02-04 | ||
| PCT/EP2003/000777 WO2003066055A1 (en) | 2002-02-04 | 2003-01-27 | Quinoline derivatives as npy antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005523901A JP2005523901A (ja) | 2005-08-11 |
| JP2005523901A5 true JP2005523901A5 (enExample) | 2005-12-22 |
| JP4216196B2 JP4216196B2 (ja) | 2009-01-28 |
Family
ID=27635782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565479A Expired - Fee Related JP4216196B2 (ja) | 2002-02-04 | 2003-01-27 | Ｎｐｙアンタゴニストとしてのキノリン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6696467B2 (enExample) |
| EP (1) | EP1474145B1 (enExample) |
| JP (1) | JP4216196B2 (enExample) |
| KR (1) | KR100659428B1 (enExample) |
| CN (1) | CN100383124C (enExample) |
| AR (1) | AR038249A1 (enExample) |
| AT (1) | ATE392897T1 (enExample) |
| AU (1) | AU2003205679B2 (enExample) |
| BR (1) | BR0307441A (enExample) |
| CA (1) | CA2473181A1 (enExample) |
| DE (1) | DE60320529T2 (enExample) |
| ES (1) | ES2304498T3 (enExample) |
| MX (1) | MXPA04007502A (enExample) |
| PE (1) | PE20040120A1 (enExample) |
| PL (1) | PL372295A1 (enExample) |
| RU (1) | RU2298002C2 (enExample) |
| TW (1) | TW200400032A (enExample) |
| UY (1) | UY27646A1 (enExample) |
| WO (1) | WO2003066055A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| JP2004110367A (ja) * | 2002-09-18 | 2004-04-08 | Hitachi Ltd | 記憶装置システムの制御方法、記憶制御装置、および記憶装置システム |
| US7317025B2 (en) * | 2003-09-24 | 2008-01-08 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Non-peptidic NPY Y2 receptor inhibitors |
| CN1905873A (zh) | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| AU2006299671A1 (en) * | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd | Substituted quinolines as inhibitors of leukotriene biosynthesis |
| RU2314295C2 (ru) * | 2006-03-01 | 2008-01-10 | Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" | 2-гетарилзамещенные 1,3-трополона, способ их получения (варианты) и фармацевтическая композиция антимикробного действия |
| WO2008141077A1 (en) * | 2007-05-10 | 2008-11-20 | Janssen Pharmaceutica N.V. | Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives |
| BRPI0811745B1 (pt) * | 2007-05-17 | 2019-06-04 | Helperby Therapeutics Limited | Compostos de 4-(pirrolidin-1-il)quinolina, uso e processo para a preparação dos mesmos, formulação farmacêutica -- |
| WO2010056865A1 (en) | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Quinoline derivatives as ion channel modulators |
| CR20170071A (es) * | 2009-06-29 | 2017-03-28 | Agios Pharmaceuticals Inc | Compuestos terapeuticos y composiciones |
| WO2012074862A2 (en) * | 2010-12-03 | 2012-06-07 | Dow Agrosciences Llc | Processes for the preparation of enamines |
| ES2675510T3 (es) | 2011-02-18 | 2018-07-11 | Endo Pharmaceuticals Inc. | Compuestos aminoindano y uso de los mismos en el tratamiento del dolor |
| EP2723717A2 (en) | 2011-06-24 | 2014-04-30 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
| AU2012272898A1 (en) | 2011-06-24 | 2013-04-11 | Amgen Inc. | TRPM8 antagonists and their use in treatments |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| US9044482B2 (en) | 2012-08-15 | 2015-06-02 | Asana Biosciences, Llc | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
| SI3102576T1 (sl) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals, Llc | Inhibitorji dihidropirolopiridina ROR-gama |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
| WO2017087608A1 (en) | 2015-11-20 | 2017-05-26 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| SMT202200465T1 (it) | 2016-07-14 | 2023-01-13 | Crinetics Pharmaceuticals Inc | Modulatori della somatostatina e loro usi |
| TWI774767B (zh) * | 2017-05-12 | 2022-08-21 | 瑞士商多蒂孔股份有限公司 | 茚烷衍生物及其在有機電子產品的用途 |
| KR20200053481A (ko) | 2017-07-24 | 2020-05-18 | 비타이 파마슈티컬즈, 엘엘씨 | RORγ의 억제제 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
| MX2020001793A (es) * | 2017-08-17 | 2020-07-22 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. |
| CN111868049B (zh) | 2018-01-17 | 2023-06-30 | 克林提克斯医药股份有限公司 | 制备促生长素抑制素调节剂的方法 |
| RU2702648C1 (ru) * | 2019-07-11 | 2019-10-09 | федеральное государственное автономное образовательное учреждение высшего образования «Южный федеральный университет» | 5,7-Ди(трет-бутил)-2-(4,7-дихлор-8-метил-5-нитрохинолин-2-ил)-4-нитро-1,3-трополон, обладающий цитотоксической активностью |
| CN116456968B (zh) | 2020-09-09 | 2026-03-20 | 克林提克斯医药股份有限公司 | 生长抑素调节剂的制剂 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4035367A (en) * | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| CA2133620A1 (en) * | 1993-10-28 | 1995-04-29 | Werner Hofheinz | Aminoquinoline derivatives |
| RU2161967C2 (ru) * | 1994-08-18 | 2001-01-20 | Дзе Проктер Энд Гэмбл Компани | Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора |
| US5552411A (en) * | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
| US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| PT1105123E (pt) | 1998-08-14 | 2004-08-31 | Hoffmann La Roche | Composicoes farmaceuticas contendo inibidores da lipase e quitosano |
| CA2340056C (en) | 1998-08-14 | 2007-01-09 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors |
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| DE10064105A1 (de) * | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| AU2002338896B2 (en) * | 2001-05-21 | 2006-04-27 | F.Hoffman-La Roche Ag | Quinoline derivatives as ligands for the neuropeptide Y receptor |
-
2003
- 2003-01-27 KR KR1020047012036A patent/KR100659428B1/ko not_active Expired - Fee Related
- 2003-01-27 CN CNB038032805A patent/CN100383124C/zh not_active Expired - Fee Related
- 2003-01-27 MX MXPA04007502A patent/MXPA04007502A/es active IP Right Grant
- 2003-01-27 AT AT03702533T patent/ATE392897T1/de not_active IP Right Cessation
- 2003-01-27 PL PL03372295A patent/PL372295A1/xx not_active Application Discontinuation
- 2003-01-27 DE DE60320529T patent/DE60320529T2/de not_active Expired - Fee Related
- 2003-01-27 BR BR0307441-2A patent/BR0307441A/pt not_active IP Right Cessation
- 2003-01-27 ES ES03702533T patent/ES2304498T3/es not_active Expired - Lifetime
- 2003-01-27 WO PCT/EP2003/000777 patent/WO2003066055A1/en not_active Ceased
- 2003-01-27 AU AU2003205679A patent/AU2003205679B2/en not_active Ceased
- 2003-01-27 RU RU2004126936/04A patent/RU2298002C2/ru not_active IP Right Cessation
- 2003-01-27 CA CA002473181A patent/CA2473181A1/en not_active Abandoned
- 2003-01-27 EP EP03702533A patent/EP1474145B1/en not_active Expired - Lifetime
- 2003-01-27 JP JP2003565479A patent/JP4216196B2/ja not_active Expired - Fee Related
- 2003-01-30 TW TW092102218A patent/TW200400032A/zh unknown
- 2003-01-31 PE PE2003000111A patent/PE20040120A1/es not_active Application Discontinuation
- 2003-01-31 AR ARP030100304A patent/AR038249A1/es not_active Application Discontinuation
- 2003-02-03 UY UY27646A patent/UY27646A1/es not_active Application Discontinuation
- 2003-02-04 US US10/358,006 patent/US6696467B2/en not_active Expired - Fee Related